Clinical Trials Sponsored by Atara Biotherapeutics

Total 386 results

Atara Biotherapeutics

Recruiting

A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

High-grade B-cell Lymphoma | MCL | Diffuse Large B-cell Lymphoma (DLBCL) | Relapsed/Refractory B-cell Non-Hodgkin Lymphoma | DLBCL/High-grade B-cell Lymphoma With MYC and BCL2 Rearrangements | Anaplastic Lymphoma Kinase-Positive Large B-Cell Lymphoma | LBCL With IRF4 Rearrangement | High-grade B-cell... and other conditions

United States
Atara Biotherapeutics

Recruiting

A Study to Evaluate Tabelecleucel in Participants With Epstein-barr Virus-associated Diseases

Lymphoproliferative Disorders | Leiomyosarcoma | Stem Cell Transplant Complications | Solid Organ Transplant Complications | Epstein-Barr Virus (EBV)-Associated Diseases | EBV+ Post-transplant Lymphoproliferative Disease (EBV+ PTLD) | Allogeneic Hematopoietic Cell Transplant | EBV+ Sarcomas | EBV+ Lymphoproliferative... and other conditions

United States, Austria, Belgium, France, Italy, Spain, United Kingdom
Atara Biotherapeutics

Recruiting

Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy (ALLELE)

Lymphoproliferative Disorders | Stem Cell Transplant Complications | Solid Organ Transplant Complications | Allogeneic Hematopoietic Cell Transplant | Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD)

United States, Austria, Australia, Belgium, Canada, France, Italy, Spain, United Kingdom
Atara Biotherapeutics

No longer available

Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies

Lymphoproliferative Disorders | Stem Cell Transplant Complications | Epstein-Barr Virus (EBV) Infections | EBV+ Associated Lymphoma | EBV+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD) | Epstein-Barr Viremia | Lymphoma, AIDS-related | Epstein-Barr Virus-associated Lymphoproliferative... and other conditions
Atara Biotherapeutics

Terminated

Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis (EMBOLD)

Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple Sclerosis

United States, Australia, Canada
Atara Biotherapeutics

No longer available

Expanded Access Protocol of ATA230 (Third-Party Donor-Derived CMV-CTLs) for the Treatment of CMV Viremia or Disease

CMV Viremia | CMV Disease
Atara Biotherapeutics
Merck Sharp & Dohme LLC

Terminated

Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)

Nasopharyngeal Carcinoma | Nasopharyngeal Neoplasms | Epstein-Barr Virus Infections | Epstein-Barr Viraemia | Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)

United States
Memorial Sloan Kettering Cancer Center
Atara Biotherapeutics

Completed

Dose Escalation Trial of WT1-Sensitized T Cells for Residual or Relapsed Leukemia After Allogeneic Hematopoietic Progenitor Cell Transplantation

Leukemia | Myelodysplastic Syndrome

United States
Memorial Sloan Kettering Cancer Center
Atara Biotherapeutics

Completed

Primary Transplant Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation

Cytomegalovirus

United States
Atara Biotherapeutics
Memorial Sloan Kettering Cancer Center

Completed

Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies

EBV-induced Lymphomas | EBV-associated Malignancies | Transplant Patients With EBV Viremia at High Risk for Developing a Recurrent EBV Lymphoma

United States
Memorial Sloan Kettering Cancer Center
Atara Biotherapeutics

Recruiting

Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma

Malignant Pleural Mesothelioma (MPM)

United States
Atara Biotherapeutics
National Cancer Institute (NCI); Memorial Sloan Kettering Cancer Center

Completed

Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies

EBV-induced Lymphomas | EBV-associated Malignancies | Transplant Patients With EBV Viremia at High Risk of Developing a Recurrent EBV Lymphoma

United States
Patara Pharma

Completed

Treatment of Refractory Chronic Cough With PA101

Refractory Chronic Cough

Netherlands, United Kingdom
Patara Pharma

Completed

Treatment of Uremic Pruritus With PA101B

Uremic Pruritus

United States
Patara Pharma

Completed

Treatment of Indolent Systemic Mastocytosis With PA101

Systemic Mastocytosis | Mastocytosis | Indolent Systemic Mastocytosis

France, Germany, Spain, Italy, Netherlands
Universitas Sumatera Utara

Not yet recruiting

The Role of Thiamine After Transcatheter Closure in Children With Left-to-Right Shunt Congenital Heart Disease

Atrial Septal Defect | Congenital Heart Disease | Patent Ductus Arteriosus | Ventricular Septal Defect | Thiamine Deficiency

Indonesia
Universitas Sumatera Utara

Completed

Mineral and Enzyme Deficiency Diseases Associated With Nutritional Diseases in Society

Nutrient Deficiency

Indonesia
Universitas Sumatera Utara

Completed

Soy, Catfish, Anchovy, and Rice Supplementation Increases 25(OH)D Serum Levels in Tuberculosis Patients With Complications

Tuberculosis

Indonesia
Universitas Sumatera Utara

Unknown

Soil-transmitted Helminth Reinfection Rates After Single and Repeated School Hygiene Education

Helminthiasis | Children, Only | Hookworm Infections | Trichuris Infection | Ascaris Infection

Indonesia
Universitas Sumatera Utara

Completed

Effect of Thiamine on Serum Glucagon And Reactive Oxygen Species (ROS)

Sepsis | Thiamine Deficiency

Indonesia
Universitas Sumatera Utara

Completed

The Use of the 25 (OH) D Saliva Test as a Substitute for the 25 (OH) D Serum Test in Healthy People

Nutritional Deficiency

Indonesia
Universitas Sumatera Utara

Completed

Sex Differences in Neuropeptide Y Serum, But Not in Fat Intake and Body Mass Index

Nutrient Deficiency

Indonesia
Universitas Sumatera Utara

Completed

The Role of Vitamin D, A, and Beta Carotene in Tuberculosis Patients With Vitamin D Receptor Gene Polymorphism

Tuberculosis

Indonesia
Universitas Sumatera Utara

Recruiting

The Association Between Anemia and Cardiomegaly

Cardiomegaly | Anemia in Children

Indonesia
Universitas Sumatera Utara

Completed

Neuroprotective Effects of ACTH4-10PRO8-GLY9-PRO10

Ketamine-Induced Neurotoxicity

Indonesia
Universitas Sumatera Utara

Completed

Role and Value of Inflammatory Markers in Brain Tumors : A Case Controlled Study

Brain Tumor

Indonesia
Universitas Sumatera Utara

Completed

Zinc Supplementation During Pregnancy: Analysis of Maternal Serum Zinc, Cord Blood Osteocalcin and Neonatal Birth Length

Zinc Deficiency | Birth Length

Indonesia
Barinthus Biotherapeutics

Not yet recruiting

VTP-1000 in Adults With Celiac Disease

Celiac Disease
Fore Biotherapeutics

Recruiting

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

Cancer Harboring BRAF Alterations

United States, Germany, Spain, United Kingdom, Korea, Republic of, Italy, France, Sweden, Canada
Sonnet BioTherapeutics

Recruiting

Phase 1 Study of SON-1010 in Adult Patients With Advanced Solid Tumors

Advanced Solid Tumor

United States
Tavotek Biotherapeutics

Active, not recruiting

Study of TAVO101 in Healthy Volunteers

Healthy Subjects

Australia
Tavotek Biotherapeutics

Completed

Study of TAVO103A in Healthy Volunteers

Healthy Subjects

United States
Revolo Biotherapeutics

Completed

A Study to Assess the Efficacy, Safety and Tolerability of IRL201104 in Adults With Active Eosinophilic Esophagitis

Eosinophilic Esophagitis

United States
Revolo Biotherapeutics

Completed

Safety, Tolerability, and Pharmacokinetics of IRL201104 in Healthy Volunteers

Healthy Volunteer

United States
Sonnet BioTherapeutics

Completed

Study of SON-1010 (IL12-FHAB) in Healthy Adults

Healthy Adult

Australia
Aeglea Biotherapeutics

Terminated

A Multiple Ascending Dose Study of ACN00177 (Pegtarviliase) in Subjects With CBS Deficiency

Homocystinuria Due to Cystathionine Beta-Synthase Deficiency

United States, United Kingdom, Australia
Fore Biotherapeutics

Completed

NovellusDx Tissue Collection Protocol

Patients That Have Been Diagnosed With Colorectal Cancer | Patients Eligible for Tumor Biopsy

Israel
Eleven Biotherapeutics

Withdrawn

Safety Study of Intravitreal EBI-031 Given as a Single or Repeat Injection to Subjects With Diabetic Macular Edema

Diabetic Macular Edema
Eleven Biotherapeutics

Unknown

Study of EBI-005 in Dry Eye Disease (DED) (EBI-005)

Dry Eye

United States
Tavotek Biotherapeutics

Recruiting

A Study of TAVO412 in Patients With Cancer (TAVO412)

Cancer

United States
Excision BioTherapeutics

Recruiting

Study of EBT-101 in Aviremic HIV-1 Infected Adults on Stable ART

HIV-1-infection

United States
Sonnet BioTherapeutics

Terminated

SON-080 in Patients With Persistent Chemotherapy-induced Peripheral Neuropathy (CIPN)

Chemotherapy-induced Peripheral Neuropathy (CIPN)

Australia
Fore Biotherapeutics

Active, not recruiting

A Study of FORE8394 as a Single Agent in Patients With Advanced Unresectable Solid Tumors

Advanced Unresectable Solid Tumors | BRAF-mutated Tumors

United States
Alethia Biotherapeutics

Completed

AB-16B5 Combined With Docetaxel in Subjects With Metastatic Non-Small Cell Lung Cancer (EGIA-002)

NSCLC Stage IV

United States, Canada
Excision BioTherapeutics

Enrolling by invitation

Long-Term Follow-Up Study of HIV-1 Infected Adults Who Received EBT-101

HIV-1-infection

United States
Aeglea Biotherapeutics

Terminated

A Study of Safety of Weekly Subcutaneous Pegzilarginase in Subjects With Arginase 1 Deficiency

Arginase I Deficiency | Hyperargininemia

Canada
Aeglea Biotherapeutics

Completed

A Study of AEB1102 (Pegzilarginase) in Patients With Arginase I Deficiency (AEB1102)

Arginase I Deficiency | Hyperargininemia

United States, Canada, United Kingdom, Portugal
Aeglea Biotherapeutics

Completed

Efficacy and Safety of Pegzilarginase in Patients With Arginase 1 Deficiency

Arginase I Deficiency | Hyperargininemia

United States, Italy, Canada, France, United Kingdom, Austria, Germany
Revolo Biotherapeutics

Completed

Allergen Challenge Trial of IRL201104 in Seasonal Allergic Rhinitis

Seasonal Allergic Rhinitis

United Kingdom
Revolo Biotherapeutics

Completed

Safety and PK of Repeated Doses of IRL201104 in Healthy Volunteers

Healthy Volunteer

United Kingdom

Clinical Trials Sponsored by Atara Biotherapeutics

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Oman

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations